Clinical Trials Logo
  1. Home
  2. Refractory Ascites
  3. NCT04621617

Midodrine and Albumin in Patients With Refractory Ascites

Refractory Ascites Clinical Trial

Official title:
Midodrine and Albumin in Patients With Refractory Ascites. A Randomised Controlled Trial.

Clinical Trial Summary

Refractory ascites is seen in 5-10% of patients with cirrhosis.Decompensated cirrhosis with refractory ascites has a mortality rate of around 40% in a year and a median survival of 6 months.Portal hypertension and splanchnic vasodilation are major factors in the development of ascites.The treatment of refractory ascites involves salt restriction, diuretics, large volume paracentesis (LVP), transjugular Intrahepatic Portosystemic shunt (TIPS) and Liver Transplantation (LT). Currently the only curative treatment is LT. However, LT is limited due to organ shortage and high cost. Long-term human albumin (HA) administration in patients with uncomplicated and refractory ascites, has shown to improve survival or delay the complications of cirrhosis. Midodrine, an oral α1- adrenergic agonist has been used in refractory ascites with variable results. However, there is no study on the use of long term Midodrine and HA in patients with refractory ascites. Therefore, we plan to study the effect of long term midodrine and HA in patients with refractory ascites.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04621617
Study type Interventional
Source Postgraduate Institute of Medical Education and Research
Contact Virendra Singh, MD, DM
Phone 0172-275-6338
Email virendrasingh100@hotmail.com
Status Not yet recruiting
Phase Phase 3
Start date November 2020
Completion date April 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04050683 - Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt (TIPS) N/A
Active, not recruiting NCT01438970 - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function Phase 2
Completed NCT00240045 - The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction Phase 2/Phase 3
Recruiting NCT05700708 - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Terminated NCT02026609 - Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS) N/A
Recruiting NCT01558895 - Infrared Ray Heat Treatment in Liver Cirrhosis Patients With Refractory Ascites Phase 2/Phase 3
Recruiting NCT04043858 - Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children N/A
Completed NCT01532427 - ALFApump System Post Marketing Surveillance Registry
Completed NCT01440829 - The Effectiveness of L-ornithine-L-aspartate (LOLA) on Plasma Ammonia in Cirrhotic Patients After TIPS Phase 2/Phase 3
Completed NCT00870662 - A Feasibility Study of the Automated Fluid Shunt (AFS) for Automated Ascites Removal N/A
Active, not recruiting NCT05434286 - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Hepatorenal Syndrome-Acute Kidney Injury
Completed NCT06196723 - Early Transjugular Intrahepatic Portosystemic Shunts Improve Survival in Patients With Cirrhosis and Recurrent Ascites